174561-04-7

Basic information

• Product Name: [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol
• Synonyms: [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol
• CAS NO: 174561-04-7
• Molecular Formula: C₁₃H₁₈FNO
• Molecular Weight: 223.2865232
• Mol File: 174561-04-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol(174561-04-7)
• EPA Substance Registry System: [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol(174561-04-7)

Safety Data

• Hazardous Substances Data: 174561-04-7(Hazardous Substances Data)

Usage

Description

[1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol is a chemical compound with the molecular formula C14H19FNO, derived from piperidine and featuring a piperidin-4-yl-methanol functional group attached to a 4-fluoro-benzyl group. [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol holds potential pharmaceutical properties and is of interest in the development of drugs targeting neurological disorders and as a precursor in organic synthesis. Its structure, which includes a piperidine ring, is a common feature in many bioactive molecules, making it a promising candidate for medicinal chemistry research and drug discovery.

Uses

Used in Pharmaceutical Industry:
[1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol is used as a potential drug candidate for the development of medications targeting neurological disorders due to its unique chemical structure and potential pharmaceutical properties.
Used in Organic Synthesis:
[1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol is also used as a precursor in organic synthesis, where its specific functional groups and structural features can be utilized to create a variety of other bioactive molecules for further research and development.
Further studies and research are necessary to fully understand the potential uses and properties of [1-(4-Fluoro-benzyl)-piperidin-4-yl]-methanol, as its pharmaceutical and synthetic applications are still being explored.

Upstream product

• 193538-24-8 1-[(4-Fluorophenyl)methyl]-4-(ethoxycarbonyl)-piperidine 
• 6457-49-4 4-piperidinemethanol 
• 352-11-4 1-chloromethyl-4-fluorobenzene 

Downstream Products

• 333363-88-5 1-[(4-Fluorophenyl)methyl]-4-piperidinecarboxaldehyde 
• 333363-89-6 4-[((2-diphenylmethoxy)amino)methyl]-1-[(4-fluorophenyl)methyl]piperidine 
• 174561-02-5 4-aminomethyl-1-(p-fluorobenzyl)piperidine 

Relevant articles and documents

Design and synthesis of Rho kinase inhibitors (II)

In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay.

N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith

N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl]piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.